REGULATORY
Council Approves Subsidies for Retreatment with 3-Drug Combination Therapies Using Protease Inhibitors Other than Simeprevir
The Ministry of Health, Labor and Welfare’s (MHLW) hepatitis treatment strategy council (chairman: Norio Hayashi, director of Kansai Rosai Hospital) approved medical expense subsidies for the retreatment of hepatitis C using three-drug combination therapies including a protease inhibitor. However, eligibility…
To read the full story
REGULATORY
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
- Ueno Vows to Advance Drug Innovation, Advanced Medicine in 2nd Term
September 24, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





